BioAge
Founded Year
2015Stage
IPO | IPOTotal Raised
$297MDate of IPO
9/26/2024Market Cap
0.28BStock Price
7.57Revenue
$0000About BioAge
BioAge offers clinical-stage biotechnology focused on developing therapies for metabolic diseases by targeting human aging. It has programs aimed at treating conditions like obesity and related metabolic disorders. It serves the healthcare and pharmaceutical sectors with its drug discovery and development. It was founded in 2015 and is based in Richmond, California.
Loading...
BioAge's Products & Differentiators
BGE-117
(Please note that this and all drugs developed by BioAge are pre-market and have not yet been approved by FDA). BGE-117 is a HIF-PH inhibitor that activates hypoxia signaling, increasing the body’s ability to synthesize hemoglobin, the molecule that carries oxygen in the blood. Because BGE-117 targets a critical pathway that is dysregulated as we age, it holds great promise for anemia of aging as well as several acute and chronic conditions driven by muscle aging.
Loading...
Research containing BioAge
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned BioAge in 4 CB Insights research briefs, most recently on Oct 22, 2025.
Oct 22, 2025
The longevity tech market map
Jan 16, 2025 report
State of Digital Health 2024 Report
Apr 4, 2024 report
State of Venture Q1’24 ReportExpert Collections containing BioAge
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
BioAge is included in 2 Expert Collections, including Digital Health.
Digital Health
12,122 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Artificial Intelligence (AI)
20,629 items
BioAge Patents
BioAge has filed 23 patents.
The 3 most popular patent topics include:
- rare diseases
- immune system
- immunology
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
7/17/2023 | 2/4/2025 | Inflammations, Rare diseases, Immune system, Immunology, Clusters of differentiation | Grant |
Application Date | 7/17/2023 |
|---|---|
Grant Date | 2/4/2025 |
Title | |
Related Topics | Inflammations, Rare diseases, Immune system, Immunology, Clusters of differentiation |
Status | Grant |
Latest BioAge News
Oct 29, 2025
and Sales Forecast of Drugs" report has been added to ResearchAndMarkets.com's offering. The anti-aging drugs market is estimated to grow from USD 79 million in the 2025, to USD 2.80 billion by 2040, representing a higher CAGR of 27% during the forecast period. Anti-Aging Therapeutics Market: Growth and Trends Researchers and innovators worldwide are focusing their efforts on the development of therapeutics that can extend life expectancy of an individual by targeting the pathophysiology of aging. Numerous start-ups and academic / research institutes globally are exploring a variety of anti-aging therapies at various stages of development. It is worth mentioning that anti-aging drug providing companies are using various methods, such as advancements in rigorous clinical trial services to expedite market approval procedure and incorporation of artificial intelligence to develop better anti-aging drugs. Additionally, technological advancements like organ-on-chip (promising alternative to conventional testing procedures) in the anti-aging domain has resulted in the development of targeted and effective longevity drugs. With the growing geriatric population, the ongoing R&D initiatives and the increasing funding investments, the anti-aging therapeutics market is expected to experience significant growth in the foreseen future. With the growing geriatric population, the ongoing R&D initiatives and the increasing funding investments, the anti-aging therapeutics market is expected to experience significant growth in the foreseen future. Anti-Aging Therapeutics Market: Key Insights The report delves into the current state of the anti-aging therapeutics market and identifies potential growth opportunities within industry. Some key findings from the report include: Presently, more than 65 anti-aging therapeutics are being developed worldwide; majority of the developers are small firms based in North America. These therapeutics, ranging from a variety of biologics and small molecules, are currently being investigated across different phases of development. More than 55% of partnership agreements were inked in the past two years. ~USD 4 billion has been invested by both private and public investors, since 2018 Over 660 patents related to anti-aging therapeutics have recently been filed / granted, indicating the growing intellectual capital in this domain. 230+ articles related to anti-aging therapeutics have been published over the last four years. The market is expected to grow at an annualized rate of over 15%; the overall opportunity is anticipated to be well distributed across different types of molecules, types of aging and key geographical regions. Europe and Asia Pacific are anticipated to capture more than 75% of the market share, by 2040. Anti-Aging Therapeutics Market: Research Coverage Market Sizing and Opportunity Analysis : The report features a thorough analysis of the global anti-aging therapeutics market, in terms of the key market segments, namely type of molecule, type of aging, geographical regions and sales forecast of drugs. Market Landscape: An in-depth assessment of the companies involved in anti-aging therapeutics market, based on several relevant parameters, such as year of establishment, company size, location of headquarters, phase of development, type of aging, type of molecule, mechanism of action, type of developer. Company Competitiveness Analysis : A comprehensive competitive analysis of anti-aging therapeutics market, examining factors, such as developer strength and portfolio strength and portfolio diversity. Company Profiles : Detailed profiles of key developers engaged in the anti-aging therapeutics market, focused on overview of the company, financial information (if available), drug portfolio, and recent developments and an informed future outlook. Patent Analysis : An insightful analysis of the various patents filed / granted in anti-aging therapeutics market, based on various parameters, such as type of patent, patent publication year, geography, CPC Symbols, type of applicant, emerging focus area, patent age, patent benchmarking, patent characteristics, and patent valuation. Publication Analysis : An insightful analysis of the overall publications reported in this domain, based on various parameters, such as year of publication, type of publication and geography. Key Questions Answered in this Report How many companies are currently engaged in this market? Which are the leading companies in this market? What factors are likely to influence the evolution of this market? What is the current and future market size? What is the CAGR of this market? How is the current and future market opportunity likely to be distributed across key market segments? Key Players in the Anti-aging Therapeutics Market Profiled in the Report Include AgelessRx ANOVA Institute of Regenerative Medicine Betterhumans BioAge Labs bioXcellerator Cambrian Biopharma Gero.ai, Mayo Clinic Rejuvenate Bio UT Health San Antonio Reasons to Buy this Report The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants. Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies. The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects. Additional Benefits Complimentary Excel Data Packs for all Analytical Modules in the Report 15% Free Content Customization Detailed Report Walkthrough Session with Research Team Report Segmentation Type of Molecule Biologics Small Molecules Type of Aging Cellular Aging Immune Aging Metabolic Aging Others Geographical Regions North America Europe Asia Pacific Rest of the World For more information about this report visit https://www.researchandmarkets.com/r/l1x5iz About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. View source version on businesswire.com: https://www.businesswire.com/news/home/20251029381603/en/ Contacts ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
BioAge Frequently Asked Questions (FAQ)
When was BioAge founded?
BioAge was founded in 2015.
Where is BioAge's headquarters?
BioAge's headquarters is located at 1445A South 50th Street, Richmond.
What is BioAge's latest funding round?
BioAge's latest funding round is IPO.
How much did BioAge raise?
BioAge raised a total of $297M.
Who are the investors of BioAge?
Investors of BioAge include Felicis, Andreessen Horowitz, OrbiMed, Cormorant Asset Management, Lilly Ventures and 23 more.
Who are BioAge's competitors?
Competitors of BioAge include Brightseed and 4 more.
What products does BioAge offer?
BioAge's products include BGE-117 and 2 more.
Loading...
Compare BioAge to Competitors
Atomwise develops machine learning-based discovery engines and uses artificial intelligence (AI)-based neural networks to help discover new medicines. It predicts drug candidates for pharmaceutical companies, start-ups, and research institutions, and designs drugs using computational drug design. It was formerly known as Chematria. The company was founded in 2012 and is based in San Francisco, California.
Canomiks is a technology company focused on the functional food, beverage, dietary supplement, and cosmeceutical industries. The company offers a genomics and AI-based platform that develops new formulations and assesses the biological efficacy and safety of ingredients and formulations. Canomiks serves the functional food and beverage, dietary supplement, and skincare industries. It was founded in 2016 and is based in Rochester, Minnesota.
Rockfish Bio focuses on the development of senolytic therapies within the biotechnology sector. The company's main offerings include compounds designed to treat age-related diseases by targeting and eliminating senescent cells to promote healthy aging. Rockfish Bio's therapies are applicable to a range of conditions such as chronic kidney disease, liver fibrosis, and neurodegenerative diseases. It was founded in 2021 and is based in Wien, Austria.
Viome operates as a health and longevity company. It specializes in preventing, diagnosing, and reversing chronic diseases and aging through its at-home health tests and personalized nutrition. The company's main offerings include at-home microbiome health tests that utilize advanced RNA sequencing technology to generate health scores and nutrition recommendations tailored to an individual's unique biology. It was founded in 2016 and is based in Bellevue, Washington.
Indena is a company dedicated to the identification, development and production of active principles derived from plants, for use in the pharmaceutical, health-food and cosmetics industries. Indena, a privately owned Italian company, has around 700 employees, including 10% dedicated to full-time research, aims to manage cultivation, manufacturing, and distribution operations in more than 40 countries throughout the world. The key to Indena's success is its research, covering: the screening of medicinal plants for their pharmacological benefits; the identification of new active principles; and the development of extraction and purification systems at the cutting-edge of industrial application. The phyto-chemical research is carried out in Indena's own Research Center in Settala, Italy. Indena also co-operates with the world's most prestigious universities and private research institutions in the biological assessment of safety and effectiveness up to clinical phase I. One of the main strategic objectives of the research is the development of new active principles for pharmaceutical applications. This is also an indispensable base for the health-food and cosmetics industries. In the pharmaceutical sector Indena is currently focusing on the development of anti-cancer treatments, following the successes of paclitaxel, as well as on anti-microbial and on anti-viral drugs. Also under study are active principles for the treatment of pathologies and dysfunction of the central nervous system, such as depression, anxiety, impotence, sleep disorders, and algesia. Today Indena is also concentrating its efforts on the industrial production of high-quality standardised active principles derived from plants, which are important ingredients in health food products. In fact, the company produces standardised extracts from edible plants that are traditionally recognised as having therapeutic properties, as well as from plants that have proven pharmacological value. Indena's research and production activities are particularly attentive to plant-based principles that have anti-oxidant properties and are effective in preventing damage caused by free radicals. Backed by over 80 years of botanical experience, the Italian company has developed a plantation network, managed by experts, to supply its research and production centers with officinal plants, while at the same time ensuring bio-diversity and protecting the ecosystem balance from uncontrolled harvesting. Today more than 60% of the raw material used in the manufacturing process comes from cultivation. Indena's decades-long global presence in the plant extraction industry is a guarantee of its in-depth knowledge and understanding of the business, market trends and legal considerations, through constant communication and interaction between the company's experts and the major international regulatory authorities such as WHO, EMEA, and ESCOP, and main pharmacopoeias.
Onegevity is a consumer health intelligence company, which combines a multi-omic AI platform with consumer-friendly products and digital services. The Health Intelligence platform can accept inputs from lab work, wearables, test results, clinical intake data, and virtually any other health and wellness information. From there, it uses AI to “map” the complex and dynamic metabolic outputs from an individual and compare to individuals alike. It can provide personalized lifestyle recommendations including nutrition, supplements, exercise/lifestyle, and can further recommend individualized follow-up testing, educational needs, and more. The platform can be used by an individual, a health-care practitioner, or for corporate wellness purposes.
Loading...